Patent ID: 11879010
Assignee: THE CHARLOTTE MECKLENBURG HOSPITAL AUTHORITY
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 0:
1. A method of inducing cytotoxicity in a cancer cell in a subject having, suspected of having, or at risk of having cancer, the method comprising:
(a) contacting the cancer cell with a first antibody or fragment thereof, wherein the first antibody or fragment thereof comprises a first antigen binding portion and a targeting ligand and wherein the cancer cell comprises a first antigen on the surface of the cancer cell, under conditions whereby the first antigen binding portion of the first antibody or fragment thereof binds the first antigen on the surface of the cancer cell, wherein the first antigen is CD20, the first antigen binding portion is a CD20 binding portion, and the targeting ligand is tetrazine; and
(b) contacting the cancer cell of step (a) with a natural killer (NK) cell comprising a targeting agent specific for the targeting ligand of the first antibody or fragment thereof, wherein the targeting agent is trans-cyclooctene (TCO) and binds in vivo to the targeting ligand of the first antibody or fragment thereof,
thereby inducing cytotoxicity in the cancer cell.